Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Daraxonrasib scores a plenary session late-breaker.
BeOne's degrader BG-60366 appears to have been discontinued.
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
The disclosure comes as another of Arcus's TIGIT trials flops.
Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
First-in-human results prompt a biomarker-defined approach for CID-078.
